Skip to main content

Aileron Therapeutics, Inc. (ALRN)

NASDAQ: ALRN · IEX Real-Time Price · USD
0.608 0.050 (9.00%)
Dec 7, 2021 12:04 PM EST - Market open
Market Cap55.07M
Revenue (ttm)n/a
Net Income (ttm)-24.36M
Shares Out90.57M
EPS (ttm)-0.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume379,784
Open0.560
Previous Close0.558
Day's Range0.555 - 0.612
52-Week Range0.542 - 2.330
Beta2.60
AnalystsStrong Buy
Price Target3.50 (+475.7%)
Earnings DateNov 11, 2021

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in pa...

IndustryBiotechnology
IPO DateJun 29, 2017
Employees8
Stock ExchangeNASDAQ
Ticker SymbolALRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ALRN stock is "Strong Buy." The 12-month stock price forecast is 3.50, which is an increase of 475.66% from the latest price.

Price Target
$3.50
(475.66% upside)
Analyst Consensus: Strong Buy

News

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

3 weeks ago - GlobeNewsWire

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as R...

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's acti...

2 months ago - GlobeNewsWire

Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conferen...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

2 months ago - GlobeNewsWire

Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is devel...

2 months ago - Benzinga

Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924's Best-in-Class Po...

BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

2 months ago - GlobeNewsWire

Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprot...

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

2 months ago - GlobeNewsWire

Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

2 months ago - GlobeNewsWire

Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual ...

BOSTON, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients...

3 months ago - GlobeNewsWire

Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end of ...

3 months ago - GlobeNewsWire

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

4 months ago - GlobeNewsWire

Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings

Aileron Therapeutics Inc (NASDAQ: ALRN) has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy.  Aileron plans to ...

5 months ago - Benzinga

Aileron Therapeutics to be Added to the Russell Microcap® Index

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

5 months ago - GlobeNewsWire

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Pat...

-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on  Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D. and  geriatric...

6 months ago - GlobeNewsWire

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out expected ...

6 months ago - GlobeNewsWire

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients

8 months ago - GlobeNewsWire

7 Penny Stocks That Actually Have Buy Ratings

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

10 months ago - InvestorPlace

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Funda...

-- Several existing Aileron investors, including Satter Medical Technology Partners  and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to under...

10 months ago - GlobeNewsWire

Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for th...

11 months ago - GlobeNewsWire

ALRN Stock: What Investors Should Know About Aileron Therapeutics

As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.

11 months ago - InvestorPlace

Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late...

WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotecti...

WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-c...

1 year ago - GlobeNewsWire

Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher

Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EO...

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a la...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $...

1 year ago - GlobeNewsWire